ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

Area of Science:

• Oncology
• Surgical Oncology
• Molecular Pathology

Background:

• Accurate patient stratification for colorectal cancer (CRC) treatment is critical.
• Identifying prognostic biomarkers improves treatment outcome prediction and therapeutic targeting.
• ARHGAP4 has been previously implicated as a relevant biomarker in colorectal cancer.

Purpose of the Study:

• To evaluate the impact of ARHGAP4 expression on overall survival (OS) in patients with colon liver metastasis (CLM) undergoing surgical resection.
• To determine if ARHGAP4 serves as a prognostic indicator in this patient cohort.

Main Methods:

• Analysis of 251 patients who underwent CLM resection between 2006 and 2017.
• Assessment of ARHGAP4 expression levels in tumor specimens using immunohistochemistry (IHC).
• Statistical correlation analysis between ARHGAP4 expression and postoperative survival outcomes.

Main Results:

• High ARHGAP4 expression was detected in 60% of the patient cohort.
• Elevated ARHGAP4 expression correlated with adverse prognosis following hepatectomy for CLM.
• Univariate and multivariate Cox regression analyses revealed ARHGAP4 as a significant independent predictor of OS (HR=1.5).
• Other independent predictors included preoperative CEA levels and vascular invasion.

Conclusions:

• ARHGAP4 is identified as a novel prognostic biomarker for patients undergoing resection of CLM.
• This finding supports the potential clinical utility of ARHGAP4 in risk-stratifying patients with CLM.